Insulet Corporation

Valuation Analysis

About the Company

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the ri

Insulet Corporation Stock at a Glance

Insulet Corporation (PODD) is currently trading at $149.70 with a market capitalization of $10.4B. The trailing P/E ratio stands at 34.98x, with a forward P/E of 18.5x. The 52-week range spans from $140.63 to $354.88; the current price is 57.8% below the yearly high. Year-over-year revenue growth stands at +33.9%. The net profit margin stands at 10.44%.

💰 Dividend

Insulet Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

23 analysts rate Insulet Corporation (PODD) on consensus: Strong Buy. The average price target is $242.43, implying +61.95% from the current price. Analyst price targets range from $165.00 to $360.00.

Insulet Corporation: The Investment Case in Detail

Insulet Corporation (PODD) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 33.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 71.01%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 61.95% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.32 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 18.5x is meaningfully below the trailing 34.98x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 61.95% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (6.9%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Insulet Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.